Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical and Quantitative Research

Buys Focused in China, Taiwan, and Korea; Bullish Outlook Intact

5+ Month Uptrend Support Holding on MSCI ACWI (ACWI-US); China Second Chance Breakout Likely

India Finally Showing Signs of Life; Remain Overweight Taiwan, China, Korea, and the U.S.

Upgrading China to Overweight; Europe Breaking Out

China and Japan Breaking Out -- Buy; Bullish Outlook Intact; U.S. Dollar (DXY) Remains Weak

Sticking With China; Bullish Outlook Intact. Buys in Consumer Discretionary, Materials, and Tech

Europe Next to Break Out?; Bullish Outlook Intact; Remain Overweight Korea, Greece, and the U.S.

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.</li>
<li>China (Shanghai Composite) has been a major focus ever since our July 3 report titled "China and Japan Breaking Out," and it's pulling back toward 10-year base support at 3675-3725;buy.</li>
<li>Japan's TOPIX and TOPIX Small indexes remain bullish (BUY), but RS remains below multi-month resistances; we would upgrade Japan to overweight on RS breakouts.</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.
China (Shanghai Composite) has been a major focus ever since our July 3 report titled "China and Japan Breaking Out," and it's pulling back toward 10-year base support at 3675-3725;buy.
Japan's TOPIX and TOPIX Small indexes remain bullish (BUY), but RS remains below multi-month resistances; we would upgrade Japan to overweight on RS breakouts.


Zhejiang Jingxin Pharmaceutical Co., (002020 CH)

Xizang Haisco Pharmaceutical Group Co (002653 CH)

Zhejiang Wolwo Bio Pharmaceutical (300357 CH)

Zhejiang Huahai Pharmaceutical Co, Ltd. (600521 CH)

Shanghai Stock Exchange Composite Index (SHCOMP INDEX)

Shenyang Xingqi Pharmaceutical (300573 CH)

Shanghai MicroPort MedBot Group (2252 HK)

Sichuan Biokin Pharmaceutical (688506 CH)

Buys in Japan and Europe; China Pulling Back -- Buy; MSCI ACWI Uptrend Intact

Astellas Pharma

Buys in Japan and Europe; China Pulling Back -- Buy; MSCI ACWI Uptrend Intact